BED-PSMA-301: PET for Prostate Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the safety and performance of a radioactive tracer agent called rhPSMA-7.3 (18F) in Positron Emission Tomography (PET) imaging for prostate cancer.

What is the Condition Being Studied?

Prostate Cancer

Who Can Participate in the Study?

Men, 18+ who:
- Have intermediate-risk prostate cancer
- Are candidates for radical prostatectomy with pelvic lymph node dissection
- Do not have any other health conditions that may risk your ability to participate in the study

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Complete 3 study visits
-Have blood tests and physical exams
-Have the study agent (rhPSMA-7.3) given
-Have a research PET imaging scan
-Complete follow-up evaluations

Study Details

Full Title
A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer
Principal Investigator
Surgical Oncologist
Protocol Number
IRB: PRO00105041
NCT: NCT04186819
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698